Promising therapeutic targets for rheumatic diseases were the focus of a plenary session here at the ACR/ARHP 2011 Annual Scientific Meeting in November. Presenters discussed discoveries and treatments for systemic sclerosis, rheumatoid arthritis, vasculitis, and Behçet’s disease.
Pinpoint Cognitive Dysfunction in Patients with Lupus
More than 80% of SLE patients experience some type of neurologic manifestation during their disease course. The challenge for rheumatologists and other clinicians lies in appropriately diagnosing any cognitive dysfunctions that accompany lupus and better understanding the causes and risk factors of those dysfunctions. “Cognitive Function in SLE” was the focus of a talk at the 2011 ACR/ARHP Annual Scientific Meeting in November.
Ethics Forum: The Ethical Pitfalls of Clinical Trials
Your patient is deciding whether to enroll in a clinical trial at your institution and wants your advice about whether to participate.
First ARHP ‘Best of the Meeting’ Highlights Sleep Research, Osteoporosis Screening, More
“The line between ACR and ARHP sessions has totally blurred,” said Donah Zack Crawford, MA, during the presentation, “Highlights from the 2011 ARHP Sessions,” here at the 2011 ACR/ARHP Annual Scientific Meeting held in Chicago in November 2011.
A Journey Begins with the First Step
The ACR Research and Education Foundation (REF) has launched the Action Alliance network, a program that calls on rheumatologists, investigators, and health professionals to join the REF in asking patients and families to be a part of the conversation. The Action Alliance consists of two programs working together: From the Field Speakers Bureau and Patients and Families for Progress.
Magnify Rheumatology’s Legislative Impact this Month
Members of the ACR’s Executive, Government Affairs, and RheumPAC Committees, along with the Affiliate Society Council, attended 75 meetings with legislators and their staff. These meetings are critical to advancing awareness of rheumatology and the issues affecting your profession and patients.
Where Will Kinase Inhibitors Fit into the RA Treatment Mix?
Presenters at “Looking Ahead to Kinase Inhibition in Rheumatoid Arthritis,” a session here at the 2011 ACR/ARHP Annual Scientific Meeting, delved into some of the big questions that rheumatology faces with kinase inhibitor use.
Link between Autoimmunity and Environmental Exposure Needs Further Research
Rheumatology needs further cost-effective and validated methods to track the connection between environmental exposure and autoimmune diseases, including research on phenotypes, genotypes, the synergy between multiple infectious and noninfectious exposures, the timing of exposure, and the mechanisms involved, according to presenters of “Impact of Environmental Health on Autoimmunity,” a session here at the 2011 ACR/ARHP Annual Scientific Meeting held in Chicago in November 2011.
Scientists Pinpoint Three HLA Proteins Linked to Seropositive Rheumatoid Arthritis
Researchers have identified five amino acids in three HLA proteins that explain most of the association between major histocompatibility complex (MHC) and seropositive rheumatoid arthritis (RA).
Challenges and Rewards of a Physician Executive Career
The job of a physician executive offers a different set of challenges for rheumatologists familiar with research and patient care.
- « Previous Page
- 1
- …
- 95
- 96
- 97
- 98
- 99
- …
- 125
- Next Page »